Kodiak Sciences, Inc. (KOD)

Kodiak Sciences' stock has experienced significant volatility and notable events in the past six months. The stock saw a substantial surge in March 2026, following positive Phase 3 GLOW2 results for Zenkuda. In December 2025, Kodiak Sciences completed a public offering of common stock, raising $184 million. The stock also hit a new 52-week high in April 2026. Despite these positive developments, the company reported missing analysts' consensus earnings per share estimates for the quarter ending March 31, 2026. Overall, the stock has shown significant increases over the past six months.

As a clinical-stage biopharmaceutical company, Kodiak Sciences, Inc. is focused on the research, development, and commercialization of therapeutics that are still in various phases of clinical trials. Therefore, there is no direct demand seasonality for its products and services in the traditional commercial sense, as its products are not yet available on the market. The demand for its investigational therapies would be driven by the progression of clinical trials and regulatory approvals rather than seasonal factors. No specific demand seasonality has been identified for Kodiak Sciences' products or services.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for chronic, high-prevalence ophthalmic diseases, particularly those affecting the retina. The company's core strategy revolves around its proprietary Antibody Biopolymer Conjugate (ABC) Platform, which combines protein-based and chemistry-based therapies to create investigational medicines with high potency and extended durability in ocular tissues. The company's major product candidates include Tarcocimab tedromer (Zenkuda, KSI-301), KSI-501, and KSI-101, all in late-stage clinical development.

Kodiak Sciences Inc. is headquartered in Palo Alto, California, United States. The company's common stock is listed on the Nasdaq Global Market (NasdaqGM) in the US, and it is also listed on the Deutsche Boerse AG (DB) in Germany and the Bolsa Mexicana de Valores (BMV) in Mexico, indicating an international presence for its stock.

Kodiak Sciences' brand reputation over the past year has been positively impacted by key events related to its clinical pipeline. The company announced positive topline results from its Phase 3 GLOW2 study for Zenkuda in diabetic retinopathy. Kodiak Sciences has highlighted promising clinical data for KSI-101 in macular edema secondary to inflammation (MESI). The company has also been actively presenting pipeline advances and clinical data at scientific conferences, further enhancing its scientific standing.

Kodiak Sciences is primarily owned by institutional shareholders, who hold 92.98% of the company, and insiders, who own 34.36%. Major institutional and individual owners include Baker Bros Advisors LP, BlackRock Inc., Vanguard Group Inc., Point72 Asset Management LP, Braidwell LP, State Street Corp, and Victor Perlroth.